drugset / Trial / NCT04639674

Summary

The prevalence of cutaneous pruritus among hemodialysis patients is about 50% to 80%. There is only a handful of studies on the itchy skin of hemodialysis patients and the findings are to be validated. Effective drugs to treat cutaneous pruritus are not available yet. Hence, the purpose of the study is to eliminate the uremic toxins from the intestinal tract using AST-120 as a treatment measure to improve the symptom of the hemodialysis patients' cutaneous pruritus and discuss and assess its effectiveness. For this, the investigators will recruit 150 patients to validate the application potential of the AST-120 in the cutaneous pruritus brought about by uremia.

Timeline

Start
2020-07-02
Primary completion
2022-08-31
Completion
2022-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Activated Charcoal Other / unclassified 2 g Oral

Indications

No indication recorded.